Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews

The aim of this study was to analyze the potential adverse events (AEs) caused by Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, and upadacitinib, used to treat rheumatoid arthritis using spontaneous AE reports from the FDA (FAERS) and interpreting them in correlation with those...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yun-Kyoung, Song, Junu, Kim, Kyungim, Kwon, Jin-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787189/
https://www.ncbi.nlm.nih.gov/pubmed/35087406
http://dx.doi.org/10.3389/fphar.2021.792877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787189/
https://www.ncbi.nlm.nih.gov/pubmed/35087406
http://dx.doi.org/10.3389/fphar.2021.792877

Ejemplares similares